Welcome to our dedicated page for Avantor news (Ticker: AVTR), a resource for investors and traders seeking the latest updates and insights on Avantor stock.
Based in Center Valley, PA, Avantor, Inc. (NYSE: AVTR) is a global leader in providing mission-critical products and services to customers in diverse industries such as life sciences, healthcare, education and government, as well as advanced technologies and applied materials. Avantor's portfolio includes high-performance chemistries and materials marketed under reputable brand names such as J.T.Baker®, Macron Fine Chemicals™, Rankem™, BeneSphera™, and POCH™. The company's offerings span materials and consumables, equipment and instrumentation, as well as services and specialty procurement.
Operating across three geographical segments—Americas, Europe, and AMEA—Avantor generates a majority of its revenue from the Americas. Recent strategic initiatives include a partnership with Tobin Scientific to support end-to-end biopharma logistics, enhancing Avantor's ability to provide cold chain and ambient storage solutions for lab relocations and sample transport. This collaboration ensures current Good Manufacturing Practice (cGMP) compliance and aims to streamline complex logistics, thereby allowing customers to focus on advancing their research.
In addition to its commitment to operational excellence, Avantor is making strides in sustainability. The company recently introduced an innovative packaging system that optimizes product-to-package ratios, significantly reducing shipping material usage. This system has already saved thousands of pounds of filler material, exemplifying Avantor's dedication to eco-friendly practices.
Financially, Avantor reported net sales of $1.72 billion for Q3 2023, a 7.3% decline compared to the previous year, largely due to organic sales dips and COVID-19 headwinds. Despite these challenges, Avantor achieved more than 110% free cash flow conversion, facilitating ongoing debt reduction. The company also reaffirmed its FY2023 guidance, underscoring its confidence in long-term growth prospects by implementing a new operating model and advancing a $300 million cost optimization initiative.
Avantor’s global footprint gives it access to over 300,000 customer locations in 180+ countries, thereby positioning it as a crucial partner in facilitating scientific breakthroughs and innovation. For more information, visit avantorsciences.com.
Avantor, Inc. (NYSE: AVTR) reported strong financial results for Q4 and the full year 2020, showcasing resilience in a challenging environment. Q4 net sales reached $1.791 billion, up 17.5% YoY, with organic growth of 14.9%. The company generated $286 million in free cash flow. For the full year, net sales were $6.394 billion, marking a 5.8% increase, and free cash flow surged 187% to $868.2 million. Adjusted EPS rose to $0.29 in Q4, while full-year adjusted EPS increased to $0.89. The company is well-positioned as a critical partner in fighting diseases, including COVID-19.
Avantor, Inc. (NYSE: AVTR) has declared a quarterly cash dividend of $0.78 per share for its 6.250% Series A Mandatory Convertible Preferred Stock, representing a yield of 1.560%. This dividend will be payable on February 15, 2021 to shareholders on record as of February 1, 2021. The company emphasizes its commitment to enhancing shareholder value while maintaining a strong global presence in the life sciences and advanced materials sectors.
Avantor, a global provider of mission-critical products and services, will announce its fourth quarter and full year 2020 financial results after the market closes on February 3, 2021. A conference call to discuss these results will be held at 5:00 p.m. ET on the same day. Participants can join via phone or through a live webcast on the company's website. Avantor serves more than 225,000 customer locations globally, operating in key industries such as biopharma and healthcare.
Avantor (NYSE: AVTR) announced preliminary unaudited revenues for Q4 2020, estimating approximately $1.79B, reflecting an organic revenue growth of ~15%. The free cash flow is estimated at over $270M, significantly higher than $74.9M in Q4 2019. The results, to be finalized soon, align with the company's ongoing performance in life sciences and advanced materials. Management will present 2021 revenue expectations at the J.P. Morgan Healthcare Conference. Notably, these preliminary results are unaudited and may change upon final review.
Avantor (NYSE: AVTR) has announced a global initiative to support communities amid the COVID-19 pandemic. The company is donating over 1.5 million surgical masks and thermometers to schools in Mumbai and Delhi. Additionally, Avantor Foundation has granted nearly $350,000 to various organizations focusing on healthcare and STEM education. These efforts align with Avantor's mission to promote science for goodness and enhance patient outcomes through educational support and healthcare improvements.
Avantor, a leading provider of mission-critical products and services, will participate in the 39th Annual J.P. Morgan Healthcare Conference on January 11, 2021. CEO Michael Stubblefield will represent the company in a segment starting at approximately 9:10 a.m. Eastern Time. Investors can access a live webcast on Avantor's investor relations website, which will be available for replay until January 31, 2021.
With a global reach, Avantor serves over 225,000 customer locations in more than 180 countries, supporting critical research and development activities.
Avantor (NYSE: AVTR) will participate in the Evercore ISI 3rd Annual HealthCONx Virtual Conference on December 2, 2020. The event will feature a segment with Michael Stubblefield, President and CEO, starting at approximately 2:40 p.m. ET. Investors can access the live webcast via Avantor's investor relations website, and it will be available for replay until December 31, 2020. Avantor is a global leader in providing mission-critical products and services to various industries, supporting over 225,000 customer locations worldwide.
Avantor, Inc. (NYSE: AVTR) has launched a new biorepository and sample archiving facility in Frankfurt, Germany, enhancing access to samples within 24 hours for researchers. This facility is crucial for the growing demand for clinical trials, especially during the COVID-19 pandemic. Avantor boasts a 40-year heritage in biorepository services, having stored over 100 million research assets without failure. The facility has earned DGNB 'Gold' certification for sustainable construction, underscoring Avantor's commitment to ecological and economic responsibility.
Avantor, a leading global provider of mission-critical products, will participate in the Jefferies Virtual London Healthcare Conference on November 18, 2020. Michael Stubblefield, President and CEO of Avantor, is scheduled to speak at approximately 11:25 a.m. Eastern Time. Investors and attendees can access a live webcast through Avantor's investor relations website, with a replay available until November 30, 2020. Avantor serves over 225,000 customer locations globally, supporting vital research across various industries.
Avantor (NYSE: AVTR) has partnered with G-CON Manufacturing to provide mobile lab units, known as LabPODs, aimed at expediting diagnostic testing, particularly for COVID-19. These mobile labs will allow for quicker on-site testing, reducing wait times for results and potentially slowing infection rates. Avantor will supply the necessary equipment and expertise for these labs, enhancing diagnostic capabilities not only for COVID-19 but also for other microbial and analytical evaluations. This collaboration represents a significant step in transforming the accessibility of critical testing services.
FAQ
What is the current stock price of Avantor (AVTR)?
What is the market cap of Avantor (AVTR)?
What products and services does Avantor provide?
What are Avantor's key brand names?
What geographical regions does Avantor operate in?
How is Avantor contributing to sustainability?
What are Avantor's recent financial highlights?
What is Avantor's new operational strategy?
Who are Avantor's strategic partners?
How does Avantor support scientific research?
Where can I find more information about Avantor?
What are Avantor's plans for future growth?
